Concomitant medication, comorbidity and survival in patients with breast cancer - Archive ouverte HAL
Journal Articles Nature Communications Year : 2024

Concomitant medication, comorbidity and survival in patients with breast cancer

Paul Gougis
  • Function : Author
Benjamin Marande
  • Function : Author
Annabelle Ballesta
  • Function : Author
Elaine del Nery
Thierry Dubois
Samar Alsafadi
Bernard Asselain
  • Function : Author
Aurélien Latouche
Marc Espie
  • Function : Author
Enora Laas
  • Function : Author
Florence Coussy
  • Function : Author
Clémentine Bouchez
  • Function : Author
Jean-Yves Pierga
  • Function : Author
Christine Le Bihan-Benjamin
  • Function : Author
Philippe-Jean Bousquet
Judicaël Hotton
  • Function : Author
Chloé-Agathe Azencott
Fabien Reyal
Anne-Sophie Hamy
  • Function : Author

Abstract

Abstract Between 30% and 70% of patients with breast cancer have pre-existing chronic conditions, and more than half are on long-term non-cancer medication at the time of diagnosis. Preliminary epidemiological evidence suggests that some non-cancer medications may affect breast cancer risk, recurrence, and survival. In this nationwide cohort study, we assessed the association between medication use at breast cancer diagnosis and survival. We included 235,368 French women with newly diagnosed non-metastatic breast cancer. In analyzes of 288 medications, we identified eight medications positively associated with either overall survival or disease-free survival: rabeprazole, alverine, atenolol, simvastatin, rosuvastatin, estriol (vaginal or transmucosal), nomegestrol, and hypromellose; and eight medications negatively associated with overall survival or disease-free survival: ferrous fumarate, prednisolone, carbimazole, pristinamycin, oxazepam, alprazolam, hydroxyzine, and mianserin. Full results are available online from an interactive platform ( https://adrenaline.curie.fr ). This resource provides hypotheses for drugs that may naturally influence breast cancer evolution.
Fichier principal
Vignette du fichier
s41467-024-47002-3-1.pdf (3.84 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-04673415 , version 1 (21-08-2024)

Identifiers

Cite

Elise Dumas, Beatriz Grandal Rejo, Paul Gougis, Sophie Houzard, Judith Abécassis, et al.. Concomitant medication, comorbidity and survival in patients with breast cancer. Nature Communications, 2024, 15 (1), pp.2966. ⟨10.1038/s41467-024-47002-3⟩. ⟨hal-04673415⟩
75 View
17 Download

Altmetric

Share

More